Daiichi Sankyo signs pact to supply 1.4M mRNA COVID vaccine doses in Japan

17 Nov 2023
www.fiercepharma.com
VaccinemRNAClinical StudyEmergency Use AuthorizationDrug Approval
Daiichi Sankyo signs pact to supply 1.4M mRNA COVID vaccine doses in Japan
Preview
Source: FiercePharma
Under the deal, Daiichi Sankyo is on deck to supply Japan with 1.4 million doses of its shot in the 2023 fiscal year, assuming the vaccine wins approval from the country's Ministry of Health, Labor and Welfare.
As Daiichi Sankyo holds out for local approval of its omicron-adapted mRNA shot for COVID-19, the company has struck up a major supply pact in its native Japan.
Friday, Daiichi said it had reached an agreement (PDF) with Japan’s Ministry of Health, Labor and Welfare (MHLW) to supply its shot—coded DS-5670—for a vaccination program against COVID that kicked off this fall.
Under the deal, Daiichi is on deck to supply Japan with 1.4 million doses of its shot in the 2023 fiscal year, assuming the vaccine wins approval from MHLW. Daiichi submitted a supplemental application for DS-5670 in September.
The financial terms of the deal were not revealed.
To get ahead of the supply commitment, Daiichi Sankyo is now preparing its production facilities to crank out DS-5670, which the company points out is the first Japanese-made mRNA COVID-19 vaccineCOVID-19 vaccine. Production is slated to kick off this year, the company added.
The original version of DS-5670 was approved in Japan back in August and is authorized as a booster dose to prevent disease caused by SARS-CoV-2 infection.
Daiichi’s supply pact comes after the company in February reportedly started outfitting a plant in Kitamoto—an hour northeast of Daiichi’s Tokyo headquarters—to produce the shot. At the time, Daiichi confirmed that “production equipment has been installed” at the plant.
The Kitamoto facility is slated to become the first mRNA vaccine plant in the country and could be able to produce 20 million doses per year by 2024. Plans call for a production wing to be added by 2027 that would be government-funded, Nikkei Asia reported in February.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.